Detection of 19F-labeled biopharmaceuticals in cell cultures with magnetic resonance

Advanced Drug Delivery Reviews

Volumn 65, Issue 8, 2013, Pages 1056-1064

  Bartusik, Dorota ^a   Tomanek, Boguslaw ^a,b,c  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF NUCLEAR PHYSICS   (Poland)

Author keywords

19F labeled drugs; Magnetic resonance tracking

Indexed keywords

19F LABELED DRUGS; BIOPHARMACEUTICALS; CANCEROUS TISSUES; CELLULAR METABOLISM; ISOLATED TISSUES; STRONG MAGNETIC FIELDS; SYSTEMATIC STUDY; THERAPEUTIC EFFICACY;

CELL CULTURE; MAGNETIC RESONANCE IMAGING; TISSUE;

MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUCYTOSINE; FLUORINE 18; FLUOROCARBON; FLUOROURACIL; TRASTUZUMAB;

BREAST CANCER; CANCER CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; EMULSION; HUMAN; ISOTOPE LABELING; MAGNETIC FIELD; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO; SOLID TUMOR;

EID: 84881024677     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.04.010     Document Type: Review

References (142)

1. 19F MRI. Biomaterials 2012, 33:8830-8840.
2. 19F MRI). J. Inflamm. (Lond.) 2012, 9(1):24-34.
3. Hügel H.M., Jackson N. Special feature organo-fluorine chemical science. Appl. Sci. 2012, 2:558-565.
4. 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn. Reson. Med. 2008, 60(5):1066-1072.
5. 1 of perfluorocarbon blood substitute emulsions. J. Magn. Reson. Imaging 1994, 4(4):631-635.
6. 19F magnetic resonance spectroscopy. Chem. Commun. (Camb.) 2007, 28:2923-2925.
7. Martino R., Malet-Martino M., Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab. 2000, 1(3):271-303.
8. 19F- and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery. Bioconjug. Chem. 2008, 19(12):2492-2498.
9. 19F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 2010, 28(7):363-370.
10. 19F NMR. Ann. N. Y. Acad. Sci. 1987, 508:33-47.
11. Liu W., Frank J.A. Detection and quantification of magnetically labeled cells by cellular MRI. Eur. J. Radiol. 2009, 70(2):258-264.
12. Janjic J.M., Ahrens E.T. Fluorine containing nanoemulsions for MRI cell tracking. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1(5):492-501.
13. McGovern K.A., Schoeniger J.S., Wehrle J.P., Ng C.E., Glickson J.D. Gel-entrapment of perfluorocarbons: a fluorine-19 NMR spectroscopic method for monitoring oxygen concentration in cell perfusion systems. Magn. Reson. Med. 1993, 29(2):196-204.
14. 19F NMR spectroscopy of hexafluorobenzene. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41(1):161-171.
15. Srinivas M., Morel P.A., Ernst L.A., Laidlaw D.H., Ahrens E.T. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn. Reson. Med. 2007, 58(4):725-734.
16. Kadayakkara D.K.K., Janjic J.M., Pusateri L.B., Young W.-B., Ahrens E.T. In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI. Magn. Reson. Med. 2010, 64(5):1252-1259.
17. Schroy P.C., Cohen A., Winawer S.J., Friedman E.A. New chemotherapeutic drug sensitivity assay for colon carcinomas in monolayer culture. Cancer Res. 1988, 48:3236-3244.
18. Tung Y.-C., Hsiao A.Y., Allen S.G., Torisawa Y., Ho M., Takayama S. Highthroughput 3D spheroid culture and drug testing using a hanging drop array. Analyst 2011, 136:473-478.
19. Pampaloni F., Reynaud E.G., Stelzer E.H. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 2007, 8:839-845.
20. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9(4):273-285.
21. 19F-NMR. Chem. Biol. Interact. 1995, 98(2):97-112.
22. Bartusik D., Tomanek B., Lattová E., Perreault H., Fallone G. Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays. J. Pharm. Biomed. Anal. 2010, 51(5):192-201.
23. Callies R., Jackson M.E., Brindle K.M. Measurements of the growth and distribution of mammalian cells in a hollow-fiber bioreactor using nuclear magnetic resonance imaging. Biotechnology (N. Y) 1994, 12:75-78.
24. Bartusik D., Tomanek B., Lattová E., Perreault H., Fallone G. Ex vivo assays of CEM cells cultured and treated in the three dimensional cultures. Biomed. Pharmacother. 2010, 64(6):390-395.
25. Isanbora C., O'Hagan D. Fluorine in medicinal chemistry: a review of anti-cancer agents. J. Fluorine Chem. 2006, 127:303-319.
26. Organofluorine Chemistry: Principles and Commercial Applications. Topics in applied chemistry 1994, Plenum Press, New York and London. R. Banks, B.E. Smart, J.C. Tatlow (Eds.).
27. Barnette W.E. N-Fluoro-N-Alkylsulfonamides: Useful reagents for the fluorination of carbanions. J. Am. Chem. Soc. 1984, 106:452-454.
28. Leroux F.R., Manteau B., Vors J.P., Pazenok S. Trifluoromethyl ethers-synthesis and properties of a usual substitute. Beilstein J. Org. Chem. 2008, 4(13).
29. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005, 12:819-848.
30. Sham H.L. Biomedical Frontiers of Fluorine Chemistry 1996, 184-195. American Chemical Society, Washington, DC. I. Ojima, J.R. McCarthy, J.T. Welch (Eds.).
31. Woo L.W., Fischer D.S., Sharland C.M., Trusselle M., Foster P.A., Chander S.K., Di Fiore A., Supuran C.T., De Simone G., Purohit A., Reed M.J., Potter B.V. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol. Cancer Ther. 2008, 7(8):2435-2444.
32. O'Hagan D., Schaffrath C., Cobb S.L., Hamilton J.T., Murphy C.D. Biochemistry: biosynthesis of an organofluorine molecule. Nature 2002, 416:279.
33. Hesse A.L. The preparation of aliphatic fluorine compounds. Org. React. 1944, 2:49.
34. Banks R.E., Sharp D.W.A., Tatlow J.C. Fluorine, the first hundred years (1886-1986) 1986, Elsevier Sequoia, Lousanne and New York.
35. Furuya T., Klein J.E.M.N., Ritter T. Carbon-fluorine bond formation for the synthesis of aryl fluorides. Synthesis 2010, 11:1804-1821.
36. Lal G.S., Pez G.P., Syvret R.G. Electrophilic N-fluorinating agents. Chem. Rev. 1996, 96:1737-1756.
37. Olah G.A., Prakash G.K.S., Williams R.E., Field L.D., Wade K. Hypercarbon Chemistry 1987, Wiley-Interscience, New York.
38. Umemoto T., Nagayoshi M., Adachi K., Tomizawa G. Modern fluororganic chemistry. J. Org. Chem. 1998, 63:3379-3385.
39. De Lucca G.V., Liang J., De Lucca I. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. J. Med. Chem. 1999, 42:135-152.
40. Gelb M.H., Svaren J.P., Abeles R.H. Fluoro ketone inhibitors of hydrolytic enzymes. Biochemistry 1985, 24:1813-1817.
41. Liang T.-Y., Abeles R.H. pH dependence of the inhibition of chymotrypsin by a peptidyl trifluoromethyl ketone. Biochemistry 1987, 26:7603-7608.
42. Myers A.G., Barbay J.K., Zhong B. Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. J. Am. Chem. Soc. 2001, 123:7207-7219.
43. Brodbeck U., Schweikert K., Gentinetta R., Rottenberg M. Fluorinated aldehydes and ketones acting as quasi-substrate inhibitors of acetylcholinesterase. Biochim. Biophys. Acta 1979, 567(2):357-369.
44. Myers A.G., McKinstry L., Barbay J.K., Gleason J.L. Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. Tetrahedron Lett. 1998, 39:1335-1338.
45. Sham L. Biomedical Frontiers of Fluorine Chemistry 1996, 184-195. American Chemical Society, Washington, DC. I. Ojima, J.R. McCarthy, J.T. Welch (Eds.).
46. Sun S., Wang L.P., Zhang J., Yang X.Y., Zhang Q.L., Jia Z., Hu X.C., Wang B.Y. Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. Med. Oncol. 2012, 29(2):418-424.
47. 19F NMR as a powerful technique for the assay of anti-psychotic drug haloperidol in human serum and pharmaceutical formulations. J. Pharm. Biomed. Anal. 2007, 43(3):1116-1121.
48. Yi Z.M., Liu F., Zhai S.D. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. Int. J. Clin. Pract. 2010, 64(9):1310-1317.
49. Radu B.M., Bacalum M., Marin A., Chifiriuc C.M., Lazar V., Radu M. Mechanisms of ceftazidime and ciprofloxacin transport through porins in multidrug- resistance developed by extended-spectrum beta-lactamase E. coli strains. J. Fluoresc. 2011, 21(4):1421-1429.
50. Dexter D. A new topical steroid. Med. J. West 1966, 7(8):222-224.
51. 19F MR/optical imaging nanoprobes for the labeling of phagocytic and nonphagocytic immune cells. Biomaterials 2010, 31(18):4964-4967.
52. Weisenthal L.M. In vitro assays in preclinical antineoplastic drug screening. Semin. Oncol. 1981, 8:362-376.
53. 19F NMR structure analysis of membrane associated peptides. Chembiochem 2003, 4:1151-1163.
54. Nicholson J.K., Wilson I.D. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog. Nucl. Magn. Reson. Spectrosc. 1989, 21:449-501.
55. Malz F., Jancke H. Validation of quantitative NMR. J. Pharm. Biomed. Anal. 2005, 38:813-823.
56. Malet-Martino M., Gilard V., Desmoulin F., Martino R. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs. Clin. Chim. Acta 2006, 366:1-73.
57. Gillies R.J., Bhujwalla Z.M., Evelhoch J., Garwood M., Neeman M., Robinson S.P., Sotak C.H., Van der Sanden B. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2000, 2:139-151.
58. Vogler M., Dinsdale D., Sun X.-M., Young K.W., Butterworth M., Nicotera P., Dyer M.J.S., Cohen G.M. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ. 2008, 15(5):820-830.
59. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl β-d-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse, The. FASEB J. 2007, 21(9):2014-2019.
60. Ruiz-Cabello J., Walczak P., Kedziorek D.A., Chacko V.P., Schmieder A.H., Wickline S.A., Lanza G.M., Bulte J.W.M. In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn. Reson. Med. 2008, 60(6):1506-1511.
61. Hernandes M.Z., Cavalcanti S.M.T., Moreira D.R.M., Azevedo W.F., Lima Leite A.C. Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr. Drug Targets 2010, 11:303-314.
62. Bertino J.R., Mini E., Fernandes D.J. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin. Oncol. 1983, 10:2-5.
63. Semmler W., Bachert-Baumann P., Guckel F., Ermark F., Schlag P., Lorenz W.J., van Kaick G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 1990, 174:141-145.
64. March TL T.L., Johnston M.R., Duggan P.J., Gardiner J. Synthesis, structure, and biological applications of α-fluorinated β-amino acids and derivatives. Chem. Biodivers. 2012, 9(11):2410-2441.
65. 19F NMR structure analysis of membrane associated peptides. Chembiochem 2003, 4:1151-1163.
66. Goslinski T., Piskorz J. Fluorinated porphyrinoids and their biomedical applications. J. Photochem. Photobiol. C: Photochem. Rev. 2011, 12(4):304-321.
67. 19F magnetic resonance spectroscopy pharmacokinetics of 5-FU in colorectal metastases predict clinical response?. Cancer Chemother. Pharmacol. 2011, 68(1):29-36.
68. Laarhoven H.W.M., Klomp D.W.J., Kamm Y.J.L., Punt C.J.A., Heerschap A. In vivo monitoring of capecitabine metabolism in human liver by 19-fluorine magnetic resonance spectroscopy at 1.5 and 3Tesla field strength. Cancer Res. 2003, 63:7609-7612.
69. 19F MR spectroscopy at 3T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed. 2007, 20:485-492.
70. 19F magnetic resonance spectroscopy. Clin. Cancer Res. 1996, 2:339-345.
71. Sargent J.W., Seffl R.J. Properties of perfluorinated liquids. Fed. Proc. 1970, 29:1699-1703.
72. 19F MRI and HPLC-UV ex vivo. Bioorg. Chem. 2009, 37(6):193-201.
73. Riess J., Krafft M.P. Advanced fluorocarbon-based systems for oxygen and drug delivery, and diagnosis. Artif. Cells Blood Substit. Immobil. Biotechnol. 1997, 25:43-52.
74. Schaffer T., Forman D.L., Wolfson M.R. Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures. Undersea Biomed. Res. 1984, 3:287-298.
75. Bulte J.W.M. Hot spot MRI emerges from the background. Nat. Biotechnol. 2005, 2005(23):945-946.
76. Leakakos T., Schutt E.G., Cavin J.C., Smith D., Bradley J.D., Strnat D.A., del Balzo U., Hazard D.Y., Otto S., Fields T.K., Keipert P.E., Klein D.H., Flaim S.F. Pulmonary gas trapping differences among animal species in response to intravenous infusion of perfluorocarbon emulsions. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1199-1204.
77. Lowe K. Fluorinated blood substitutes and oxygen carriers. J. Fluorine Chem. 2001, 109:59-65.
78. 19F Magnetic Resonance. Fluorine Health 2008, 197-276.
79. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 2010, 62(11):1052-1063.
80. 19F) MRS and MRI in biomedicine. NMR Biomed. 2011, 24(2):114-129.
81. Gore J.C., Manning H.C., Quarles C.C., Waddell K.W., Yankeelov T.E. Magnetic resonance in the era of molecular imaging of cancer. Magn. Reson. Imaging 2011, 29(5):587-600.
82. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 2000, 41(1):55-74.
83. 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles. Angiogenesis Oct 6 2012, 10.1007/s10456-012-9310-0.
84. 19F MR imaging of 5-fluorouracil and α-fluoro-β-alanine. Magn. Reson. Imaging 1993, 11(8):1193-1201.
85. 19F MRS and MRI. MAGMA 2004, 17:288-295.
86. 19F-MR relaxometry. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44(3):649-658.
87. Fischer J.J., Rockwell S., Martin D.F. Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12(1):95-102.
88. Huang M.Q., Basse P.H., Yang Q., Horner J.A., Hichens T.K., Ho C. MRI detection of tumor in mouse lung using partial liquid ventilation with a perfluorocarbon in water emulsion. Magn. Reson. Imaging 2004, 22(5):645-652.
89. Evelhoch J.L., Gillies R.J., Karczmar G.S., Koutcher J.A., Nalcioglu O., Raghunand N., Ronen S.M., Ross B.D., Swartz H.M. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000, 2(1-2):152-165.
90. Hazendonk P., Harris R.K., Galli G., Pizzanelli S. Cross-polarization for a fluoropolymer involving multiple spin baths of abundant nuclei. Phys. Chem. Chem. Phys. 2002, 4:507-513.
91. 19F imaging agents. Magn. Reson. Med. 2011, 66(4):1116-1122.
92. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 2010, 62(11):1052-1063.
93. Mura S., Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 2012, 64(13):1394-1416.
94. Weisenthal L.M. In vitro assays in preclinical antineoplastic drug screening. Semin. Oncol. 1981, 8:362-376.
95. 19F magnetic resonance imaging. J. Magn. Reson. 1977, 28:133-136.
96. Liliemark J., Peterson C. Pharmacokinetic optimisation of anticancer therapy. Clin. Pharmacokinet. 1991, 21:213-231.
97. Wasternack C., Hause B. 30Years of 5-fluorouracil. Pharmazie 1987, 42:73-79.
98. Lee S.-J., Olsen B., Schlesinger P.H., Baker N.A. Characterization of perfluorooctylbromide-based nanoemulsion particles using atomistic molecular dynamics simulations. J. Phys. Chem. B 2010, 114(31):10086-10096.
99. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007, 21:1647-1654.
100. Ahrens T., Flores R., Xu H., Morel P.A. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 2005, 23:983-987.
101. Semmler W., Bachert-Baumann P., Guckel F., Ermark F., Schlag P., Lorenz W.J., van Kaick G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 1990, 174:141-145.
102. 19F magnetic resonance ex vivo imaging of three-dimensional cultured breast cancer cells to study the effect of d-tocopherol. Anal. Biochem. 2009, 387:315-317.
103. 19F MRI of 3D CEM cells to study the effects of tocopherols and tocotrienols. J. Pharm. Biomed. Anal. 2010, 53(3):599-602.
104. 19F MRI ex vivo. J. Pharm. Biomed. Anal. 2010, 51(4):894-900.
105. 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells. Arch. Biochem. Biophys. 2010, 493(2):234-241.
106. Lanza M., Wickline S.A. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr. Probl. Cardiol. 2003, 28:625-653.
107. Pan D., Caruthers S.D., Chen J., Winter P.M., SenPan A., Schmieder A.H., Wickline S.A., Lanza G.M. Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med. Chem. 2010, 2(3):471-490.
108. 19F magnetic resonance imaging. J. Magn. Reson. 1977, 28:133-136.
109. 19F inversion recovery echo planar imaging of perfluoro-15-crown-5-ether. Magn. Reson. Med. 1997, 32:88-97.
110. 19F a versatile reporter for noninvasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005, 12:819-848.
111. Vitu-Loas L., Thomas C., Chavaudra N., Guichard M. Radiosensitivity, blood perfusion and tumor oxygenation after perfluorobron emulsion injection. Radiother. Oncol. 1993, 27:149-155.
112. 19F NMR spectroscopy. Artif. Cells Blood Substit. Immobil. Biotechnol. 1995, 22:1243-1250.
113. Sacher R., Rämö P., Damm E.M., Liberali P., Pelkmans L. Population context determines cell-to-cell variability in endocytosis and virus infection. Nature 2009, 461:520-523.
114. Cardiff R.D. Validity of mouse mammary tumour models for human breast cancer; comparative pathology. Microsc. Res. Tech. 2001, 52:224-230.
115. Cormier R.T., Hong K.H., Halberg R.G. Secretory phospholipidies Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 1997, 17:88-91.
116. Hess M.W., Pfaller K., Ebner H.L., Beer B., Hekl D., Seppi T. 3D versus 2D cell culture implications for electron microscopy. Methods Cell Biol. 2010, 96:649-670.
117. Abbott A. Biology's new dimension. Nature 2003, 424:870-872.
118. Martin Y., Vermette P. Bioreactors for tissue mass culture: design, characterization, and recent advances. Biomaterials 2005, 26:7481-7503.
119. Takezawa T., Mori Y., Yonaha T., Yoshizato K. Characterization of morphology and cellular metabolism during the spheroid formation by fibroblasts. Exp. Cell Res. 1993, 208:430-441.
120. Ishaug-Riley S.L., Crane-Kruger G.M., Yaszemski M.J., Mikos A.G. Three-dimensional culture of rat calvarial osteoblasts in porous biodegradable polymers. Biomaterials 1998, 19:1405-1412.
121. Malone C.C., Schiltz P.M., Mackintosh A., Beutel L.D., Heinenman S.F., Dillman R.O. Characterization of human tumor-infiltrating lymphocytes expanded in hollow fiber bioreactor. Cancer Biother. Radiopharm. 2001, 16(5):381-390.
122. Vendrik C.P., Bergers J.J., De Jong W.H., Steerenberg P.A. Resistance to cytostatic drugs at the cellular level. Cancer Chemother. Pharmacol. 1992, 29:413-429.
123. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
124. Rutzky L.P., Tomita J.T., Calenoff M.A., Kahan B.D. Human colon adenocarcinoma cells. III. In vitro organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture. J. Natl. Cancer Inst. 1979, 63:893-902.
125. Minuth W.M., Stockl G., Kloth S., Dermietzel R. Construction of an apparatus for perfusion cell cultures which enables in vitro experiments under organotypic conditions. Eur. J. Cell Biol. 1992, 57:132-137.
126. Hassell T., Gleave S., Butler M. Growth inhibition in animal cell culture. The effect of lactate and ammonia. Appl. Biochem. Biotechnol. 1991, 30:29-41.
127. Sardonini C.A., Wu Y.I. Expansion and differentiation of human hematopoietic cells fromstatic cultures through small-scale bioreactors. Biotechnol. Prog. 1993, 9(2):131-137.
128. Martin I., Wendt D., Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol. 2004, 22(2):80-86.
129. Knazek R.A., Wu Y.W., Aebersold P.M., Rosenberg S.A. Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J. Immunol. Methods 1990, 127:29-37.
130. Sardonini C.A., Wu Y.J. Expansion and differentiation of human hematopoietic cells from static cultures through small-scale bioreactors. Biotechnol. Prog. 1993, 9:131-137.
131. Konemann S., Schuck A., Malath J., Rupek T., Horn K., Baumann M., Vormoor J., Rube C., Willich N. Cell heterogeneity and subpopulations in solid tumors characterized by simultaneous immunophenotyping and DNA content analysis. Cytometry 2000, 41:172-177.
132. Padron J.M., van der Wilt C.L., Smid K., Smitskamp-Wilms E., Backus H.H., Pizao P.E., Giaccone G., Peters G.J. The multilayered postconfluent cell culture as a model for drug screening. Crit. Rev. Oncol. Hematol. 2000, 36:141-157.
133. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365(14):1273-1283.
134. Wang S.C., Zhang L., Hortobagyi G.N., Hung M.C. Targeting HER-2: recent developments and future directions for breast cancer patients. Semin. Oncol. 2001, 28:21-29.
135. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER 1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003, 200:290-297.
136. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
137. Wong A.K., Ormonde P.A., Pero R., Chen Y., Lian L., Salada G., Berry S., Lawrence Q., Dayananth P., Ha P., Tavtigian S.V., Teng D.H., Bartel P.L. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 1998, 17:2279-2285.
138. Kadayakkara D.K., Beatty P.L., Turner M.S., Janjic J.M., Ahrens E.T., Finn O.J. Inflammation driven by overexpression of the hypoglycosylated abnormal MUC1 links inflammatory bowel disease (IBD) and pancreatitis. Pancreas 2010, 39(4):510-515.
139. Marsh J.A., Singh V.K., Jia Z., Forman-Kay J.D. Sensitivity of secondary structure propensities to sequence differences between α- and γ-synuclein: implications for fibrillation. Protein Sci. 2006, 15(12):2795-2804.
140. Bartusik D., Tomanek B., Fallone G. Monitoring of 3-D breast carcinoma cell culture using proton magnetic resonance imaging. Med. Chem. Res. 2010, 19(9):1153-1161.
141. 19F magnetic resonance spectroscopy. Crit. Rev. Oncol. Hematol. 2005, 56:321-343.
142. 19F NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs. systematic infusion protocols. NMR Biomed. 2004, 17:101-131.